You are in: eMedicine Specialties > Sports Medicine > Shoulder Acromioclavicular Joint InjuryArticle Last Updated: Oct 26, 2006AUTHOR AND EDITOR INFORMATIONAuthor: L Edward Seade, MD, Consulting Staff, Orthopaedic Specialists of Austin Coauthor(s): William Jay Bryan, MD, Clinical Professor, Department of Orthopedic Surgery, Baylor University College of Medicine; Reed L Bartz, MD, Consulting Staff, Division of Sports Medicine, Nebraska Orthopaedic and Sports Medicine PC; Robert Josey, MD, Consulting Staff, Department of Orthopedic Surgery, Orthopaedic Specialists of Austin Editors: David T Bernhardt, MD, Director of Adolescent and Sports Medicine Fellowship, Associate Professor, Department of Pediatrics, University of Wisconsin; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Russell D White, MD, Professor of Medicine, Department of Community and Family Medicine, University of Missouri-Kansas City School of Medicine, Truman Medical Center Lakewood; Jon Whitehurst, MD, Consulting Staff, Rockford Orthopedic Associates; Craig C Young, MD, Medical Director of Sports Medicine, Sports Medicine Fellowship Director, Professor, Departments of Orthopedic Surgery and Community and Family Medicine, Medical College of Wisconsin Author and Editor Disclosure Synonyms and related keywords: acromioclavicular joint injury, shoulder separation, shoulder dislocation, shoulder pain, AC joint injury, AC separation, AC joint disruption, acromioclavicular disruption INTRODUCTIONInjuries in and around the shoulder are common in today's athletic society. Proper knowledge of the different problems and treatment options is necessary to get patients back to their preinjury state. BackgroundAcromioclavicular (AC) joint injuries are common and often seen after bicycle wrecks, contact sports, and car accidents. The AC joint is located at the top of the shoulder where the acromion process and the clavicle meet to form a joint. Several ligaments surround this joint and depending on the severity of the injury, a person may tear one or all of the ligaments. Torn ligaments lead to AC joint sprains and separations. The distal clavicle and acromion process can also be fractured. Injury to the AC joint may injure the cartilage within the joint and can later cause arthritis of the AC joint. This article discusses the anatomy of the joint, the diagnosis of this condition, and the different treatment options. FrequencyUnited StatesInjuries to the AC joint are the most common reason that athletes seek medical attention following an acute shoulder injury. Glenohumeral dislocations (see Shoulder Dislocation) are the second most common injuries seen. Men in their second through fourth decades of life have the greatest frequency of AC joint injuries. These injuries are most often incomplete tears of the ligaments. Functional AnatomyThe AC joint is made up of 2 bones (the clavicle and the acromion), 4 ligaments, and a meniscus inside the joint.
Sport Specific BiomechanicsWhen a person falls onto their shoulder, the force pushes the tip of the shoulder down. The clavicle is usually kept in its anatomic position while the shoulder is driven down, which injures the different ligaments or causes a fracture. When the ligaments are injured they are either sprained or, in more severe cases, torn.
CLINICALHistoryAcromioclavicular (AC) joint injury should be considered in any patient complaining of pain over the superior part of the shoulder. Injuries to this part of the body are painful.
Physical
CausesSee History. DIFFERENTIALSClavicular Injuries Rotator Cuff Injury Shoulder Dislocation Shoulder Impingement Syndrome Superior Labrum Lesions
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Ibuprofen (Motrin, Ibuprin, Advil) |
|---|---|
| Description | DOC for patients with mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis. |
| Adult Dose | 200-400 mg PO q4-6h while symptoms persist; not to exceed 3.2 g/d |
| Pediatric Dose | 6 months to 12 years: 4-10 mg/kg/dose PO tid/qid >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; peptic ulcer disease, recent GI bleeding or perforation, renal insufficiency, or high risk of bleeding |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related side effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in coagulation abnormalities or during anticoagulant therapy |
| Drug Name | Ketoprofen (Oruvail, Actron, Orudis) |
|---|---|
| Description | For relief of mild to moderate pain and inflammation. Small dosages initially are indicated in small and elderly patients and in those with renal or liver disease. Doses exceeding 75 mg do not increase therapeutic effects. Administer high doses with caution, and closely observe patient for response. |
| Adult Dose | 25-50 mg PO q6-8h prn; not to exceed 300 mg/d |
| Pediatric Dose | 3 months to 12 years: 0.1-1 mg/kg PO q6-8h >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related side effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in coagulation abnormalities or during anticoagulant therapy |
| Drug Name | Naproxen (Naprelan, Anaprox, Naprosyn) |
|---|---|
| Description | For relief of mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing activity of cyclo-oxygenase, which results in a decrease of prostaglandin synthesis. |
| Adult Dose | 500 mg PO followed by 250 mg q6-8h; not to exceed 1.25 g/d |
| Pediatric Dose | <2 years: Not established >2 years: 2.5 mg/kg/dose PO; not to exceed 10 mg/kg/d |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related side effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of the drug |
| Drug Name | Indomethacin (Indocin, Indochron ER) |
|---|---|
| Description | Rapidly absorbed. Metabolism occurs in liver by demethylation, deacetylation, and glucuronide conjugation. Inhibits prostaglandin synthesis. |
| Adult Dose | 25-50 mg PO bid/tid 75 mg SR PO bid; not to exceed 200 mg/d |
| Pediatric Dose | 1-2 mg/kg/d divided PO bid/qid; not to exceed 4 mg/kg/d or 150-200 mg/d |
| Contraindications | Documented hypersensitivity; GI bleeding or renal insufficiency |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related side effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; acute renal insufficiency, hyperkalemia, hyponatremia, interstitial nephritis, and renal papillary necrosis may occur; increases risk of acute renal failure in patients with preexisting renal disease or compromised renal perfusion; reversible leukopenia may occur; discontinue if persistent leukopenia, granulocytopenia, or thrombocytopenia occurs |
| Drug Name | Diclofenac (Voltaren, Cataflam) |
|---|---|
| Description | Inhibits prostaglandin synthesis by decreasing activity of enzyme cyclo-oxygenase, which in turn decreases formation of prostaglandin precursors. |
| Adult Dose | Persistent night pain or morning stiffness: Up to 100 mg hs may help to relieve pain; not to exceed total daily dose of 200 mg |
| Pediatric Dose | >12 years: Administer as in adults <12 years: Not established |
| Contraindications | Documented hypersensitivity; do not administer into CNS; do not give to patients with peptic ulcer disease, recent GI bleeding or perforation, or renal insufficiency; do not administer to those at high risk of bleeding |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related side effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; acute renal insufficiency, hyperkalemia, hyponatremia, interstitial nephritis, and renal papillary necrosis may occur; increases risk of acute renal failure in patients with preexisting renal disease or compromised renal perfusion; low white blood cell counts occur rarely and usually return to normal in ongoing therapy; discontinuation of therapy may be necessary if persistent leukopenia, granulocytopenia, or thrombocytopenia occurs |
| Drug Name | Sulindac (Clinoril) |
|---|---|
| Description | Decreases activity of cyclo-oxygenase and in turn inhibits prostaglandin synthesis. Results in a decreased formation of inflammatory mediators. |
| Adult Dose | 150-200 mg PO bid or 300-400 qd; not to exceed 400 mg/d |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; patients in whom aspirin, iodides, or other NSAIDS induce hypersensitivity; gastrointestinal (GI) bleed; renal insufficiency |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related side effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Category D in third trimester of pregnancy; acute renal insufficiency, hyperkalemia, hyponatremia, interstitial nephritis, and renal papillary necrosis may occur; increases risk of acute renal failure in preexisting renal disease or compromised renal perfusion; low white blood cell counts occur rarely and usually return to normal in ongoing therapy; discontinuation of therapy may be necessary if persistent leukopenia, granulocytopenia, or thrombocytopenia occurs; caution in persons with anticoagulation defects or in those receiving anticoagulant therapy |
Have anti-inflammatory properties and cause profound and varied metabolic effects. Corticosteroids modify the body's immune response to diverse stimuli.
| Drug Name | Hydrocortisone (Solu-Cortef, Hydrocortone phosphate) |
|---|---|
| Description | Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability. |
| Adult Dose | Small joints: 10-25 mg intralesional Large joints: 25 mg intralesional |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; viral, fungal, or tubercular skin infections |
| Interactions | Corticosteroid clearance may decrease with estrogens; may increase digitalis toxicity secondary to hypokalemia |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in hyperthyroidism, osteoporosis, peptic ulcer, cirrhosis, nonspecific ulcerative colitis, diabetes, and myasthenia gravis |
| Drug Name | Triamcinolone (Aristospan Intra-Articular, Aristocort Forte, Kenaject-40) |
|---|---|
| Description | For inflammatory dermatosis responsive to steroids. Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing capillary permeability. |
| Adult Dose | 2-20 mg intra-articularly q3-4wk |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; fungal, viral, and bacterial skin infections |
| Interactions | Coadministration with barbiturates, phenytoin, and rifampin decreases effects of triamcinolone |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Multiple complications (eg, severe infections, hyperglycemia, edema, osteonecrosis, myopathy, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, myasthenia gravis, growth suppression) may occur; abrupt discontinuation of glucocorticoids may cause adrenal crisis |
The author has the following strict return to sports criteria that he addresses with the patients and physical therapists.

Just like any other joint in the body, once the acromioclavicular (AC) joint has been injured it has a tendency for arthritis and pain. The most common problem after these injuries is pain in the AC joint. In type III sprains, the most common setback is also instability in the clavicle from the torn ligaments.
Postoperative complications may also arise. The most common complication is mild residual instability after ligament reconstruction. This was more common when screws, sutures, suture-tape, and K-wires were being used to repair the coracoclavicular (CC) ligament tears. Infections may also occur, but are rare, occurring less than 1% of the time.
When a patient is dealing with an arthritic AC joint, the most common problem is inadequate resection of the clavicle during surgery. This causes continued AC joint pain in these patients, but is easily fixed with proper arthroscopic resection of this fragment.
Prevention of significant AC joint degenerative pathology simply consists of early diagnosis of the problem and avoidance of causative maneuvers, if possible.
Although the literature does not contain studies investigating the natural history of AC joint degenerative disease, some studies report that athletes with distal clavicle osteolysis often experience resolution of symptoms with avoidance of provocative activities.
Published studies of patients undergoing both arthroscopic and open resection have reported good or excellent results in approximately 60-100% of cases. No prospective comparisons of open versus arthroscopic treatment have been published; however, retrospective studies have shown similar long-term results. Patients undergoing arthroscopic treatment are likely to return to activity more quickly than other patients.
| Media file 1:
Classification of acromioclavicular (AC) joint injuries. | |
![]() | View Full Size Image | Media type: Illustration |
| Media file 2: Postoperative CC ligament reconstruction. The clavicle is back to its normal position. The anchor in the clavicle keeps the allograft tendon from coming off of the clavicle. Also note the distal clavicle has been excised because it had traumatic arthritis from the injury. | |
![]() | View Full Size Image | Media type: Radiograph |
| Media file 3: Type III AC joint separation. | |
![]() | View Full Size Image | Media type: Radiograph |
| Media file 4: Type III AC joint separation. | |
![]() | View Full Size Image | Media type: Radiograph |
| Media file 5: Postoperative rehabilitation. | |
![]() | View Full Size Image | Media type: Photo |
Acromioclavicular Joint Injury excerpt
Article Last Updated: Oct 26, 2006